20P Immuno-modulating effects of hyperthermia on PD-L1 and NLRC5 in ovarian cancer

Hyperthermia (HT) has been widely used as an adjuvant to chemotherapy in the treatment of ovarian cancer, it has pleiotropic effects on cellular processes involved in tumor growth and progression. Inducing cellular stress response through heat-shock proteins (HSPs) expression is one of the main hallmarks of HT. HSPs have been reported to trigger an immune activation. However, antitumor immune responses are often invalidated by immune evasion mechanisms such as the overexpression of the immunosuppressive PD-L1 and the loss of MHC class I expression.